Royce & Associates LP Purchases 840,951 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Royce & Associates LP boosted its position in Standard BioTools Inc. (NASDAQ:LAB) by 136.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,455,503 shares of the company’s stock after purchasing an additional 840,951 shares during the period. Royce & Associates LP owned approximately 0.39% of Standard BioTools worth $2,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Standard BioTools by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after purchasing an additional 9,995 shares during the last quarter. HighTower Advisors LLC boosted its position in Standard BioTools by 13.0% in the 4th quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock valued at $162,000 after buying an additional 10,690 shares during the period. Wolverine Trading LLC purchased a new stake in Standard BioTools in the 3rd quarter valued at about $27,000. Simon Quick Advisors LLC bought a new position in Standard BioTools in the 4th quarter worth about $54,000. Finally, SG Americas Securities LLC increased its position in shares of Standard BioTools by 34.2% during the fourth quarter. SG Americas Securities LLC now owns 135,927 shares of the company’s stock worth $238,000 after acquiring an additional 34,670 shares during the period. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Insider Activity

In related news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the acquisition, the director now owns 58,846,780 shares of the company’s stock, valued at $62,377,586.80. The trade was a 8.92 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 53.10% of the company’s stock.

Analyst Ratings Changes

Separately, KeyCorp lowered Standard BioTools from an “overweight” rating to a “sector weight” rating in a report on Thursday, February 27th.

Standard BioTools Price Performance

LAB stock opened at $1.16 on Friday. Standard BioTools Inc. has a 1-year low of $0.99 and a 1-year high of $3.04. The business has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.72. The company has a market capitalization of $439.62 million, a P/E ratio of -1.63 and a beta of 1.62.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.